P
Ping Wei
Researcher at Pfizer
Publications - 7
Citations - 721
Ping Wei is an academic researcher from Pfizer. The author has contributed to research in topics: Palbociclib & Cancer. The author has an hindex of 4, co-authored 6 publications receiving 611 citations.
Papers
More filters
Journal ArticleDOI
Whole-genome sequencing identifies recurrent mutations in hepatocellular carcinoma
Zhengyan Kan,Hancheng Zheng,Xiao Liu,Shuyu Li,Thomas D. Barber,Zhuolin Gong,Huan Gao,Ke Hao,Melinda D. Willard,Jiangchun Xu,Robert Hauptschein,Paul A. Rejto,Julio Fernandez,Guan Wang,Qinghui Zhang,Bo Wang,Ronghua Chen,Jian Wang,Nikki P. Lee,Wei Zhou,Zhao Lin,Zhiyu Peng,Kang Yi,Shengpei Chen,Lin Li,Xiaomei Fan,Jie Yang,Rui Ye,Jia Ju,Kai Wang,Heather Estrella,Shibing Deng,Ping Wei,Ming Qiu,Isabella H. Wulur,Jiangang Liu,Mariam Ehsani,Chunsheng Zhang,Andrey Loboda,Wing-Kin Sung,Wing-Kin Sung,Amit Aggarwal,Ronnie T.P. Poon,Sheung Tat Fan,Jun Wang,James S. Hardwick,James S. Hardwick,Christoph Reinhard,Hongyue Dai,Yingrui Li,John M. Luk,John M. Luk,John M. Luk,Mao Mao,Mao Mao +54 more
TL;DR: Findings from a whole-genome sequencing study of 88 matched HCC tumor/normal pairs, 81 of which are Hepatitis B virus (HBV) positive, find beta-catenin to be the mostrequently mutated oncogene and TP53 the most frequently mutated tumor suppressor.
Journal ArticleDOI
Evaluation of Selective γ-Secretase Inhibitor PF-03084014 for Its Antitumor Efficacy and Gastrointestinal Safety to Guide Optimal Clinical Trial Design
Ping Wei,Marlena Walls,Ming Qiu,Richard Ding,Robert H. Denlinger,Anthony C. Wong,Kosta Tsaparikos,Jitesh P. Jani,Natilie Hosea,Michelle Sands,Sophia Randolph,Tod Smeal +11 more
TL;DR: Results show that inhibition of Notch signaling by PF-03084014 while minimizing gastrointestinal toxicity presents a promising approach for development of therapies for Notch receptor–dependent cancers.
Journal ArticleDOI
Expanding control of the tumor cell cycle with a CDK2/4/6 inhibitor
Kevin Daniel Freeman-Cook,Robert Louis Hoffman,Nichol Miller,Jonathan Almaden,John Chionis,Qin Zhang,Koleen Eisele,Chaoting Liu,Cathy Zhang,Nanni Huser,Lisa Nguyen,Cinthia Costa-Jones,Sherry Niessen,Jordan Carelli,John Lapek,Scott L. Weinrich,Ping Wei,Elizabeth A. McMillan,Elizabeth Wilson,Tim S. Wang,Michele McTigue,Rose Ann Ferre,You-Ai He,Sacha Ninkovic,Douglas Carl Behenna,Tran Khanh Tuan,Sutton Scott Channing,Asako Nagata,Martha A. Ornelas,Kephart Susan Elizabeth,Zehnder Luke Raymond,Brion W. Murray,Meirong Xu,James Solowiej,Ravi Visswanathan,Britton Boras,David Looper,Nathan V. Lee,Jadwiga Bienkowska,Zhou Zhu,Zhengyan Kan,Ying Ding,Xinmeng Jasmine Mu,Cecilia Oderup,Shahram Salek-Ardakani,Michael A. White,Todd VanArsdale,Stephen Dann +47 more
TL;DR: In this article, a pyridopyrimidine with potent inhibition of CDK2/4/6 activity and efficacy in multiple in-vivo tumor models was presented.
Journal ArticleDOI
Combining CDK4/6 inhibition with taxanes enhances anti-tumor efficacy by sustained impairment of pRB-E2F pathways in squamous cell lung cancer
Joan Cao,Zhou Zhu,Hui Wang,Timothy Nichols,Goldie Y. L. Lui,Shibing Deng,Paul A. Rejto,Todd VanArsdale,James S. Hardwick,Scott L. Weinrich,Ping Wei +10 more
TL;DR: Enhanced cytotoxicity and anti-tumor effect with palbociclib plus taxanes at clinically achievable doses in multiple SqCLC models with diverse cancer genetic backgrounds are demonstrated.
Journal ArticleDOI
Synthesis and antiviral activity of HCV NS3/4A peptidomimetic boronic acid inhibitors.
Amogh Boloor,Denise Hanway,Maria Joshi,David T. Winn,Gabriel Mendez,Marlena Walls,Ping Wei,Fuxin Qian,Xiaoli Zhang,Yuliang Zhang,Michael E. Hepperle,Xinqiang Li,David Alan Campbell,Juan Manuel Betancort +13 more
TL;DR: A new series of NS3/4A protease boronic acid inhibitors is described, showing good biochemical potency and cellular activity and displaying subnanomolar to single digit nanomolar potencies in the enzymatic assays.